ARTL's cash position collapsed from $6.9M to $600K, representing a 91% decline that creates immediate liquidity concerns for this clinical-stage biotech company.
The dramatic cash burn raises serious questions about the company's ability to fund ongoing operations and clinical trials without immediate financing. With current assets falling to just $695K, ARTL appears to be in a precarious financial position that could force dilutive equity raises or operational cutbacks.
ARTL's financial position deteriorated substantially over the period, with cash and equivalents plummeting 91% to just $600K and current assets declining 73% to $695K. Net losses widened modestly to $12.9M from $9.8M, while operating losses increased 13% to $11.4M. The company's balance sheet contracted significantly with total assets falling 40% to $2.8M, painting a picture of severe capital constraints that threaten operational continuity.
Cash declined 91.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 72.8% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 40.4% — asset sales, write-downs, or balance sheet optimization underway.
Net income declined 31.1% — review whether driven by operations, interest costs, or non-recurring items.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →